Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alfuzosin hydrochloride
Drug ID BADD_D00070
Description Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70.[A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251]
Indications and Usage Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).[L9251]
Marketing Status approved; investigational
ATC Code G04CA01
DrugBank ID DB00346
KEGG ID D01692
MeSH ID C047638
PubChem ID 71764
TTD Drug ID D0H1YQ
NDC Product Code 14501-0003; 63629-2354; 65862-249; 71335-2146; 53747-019; 65977-0023; 57237-114; 63629-7907; 65862-206; 43353-945; 51655-432; 69097-844; 46014-1018; 29300-155; 51655-087; 63629-9295; 47335-956; 76282-302; 51655-967; 63629-9155; 63278-0500; 66039-826; 63629-2353; 64679-738
UNII 75046A1XTN
Synonyms alfuzosin | alphuzosine | N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide | alfusozine | alfuzosin hydrochloride | UroXatral | Benestan | Urion | Xatral | Alfetim
Chemical Information
Molecular Formula C19H28ClN5O4
CAS Registry Number 81403-68-1
SMILES CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Atrial fibrillation02.03.03.002--
Bronchitis22.07.01.001; 11.01.09.001--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Dyspepsia07.01.02.001--
Fatigue08.01.01.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Hypotension24.06.03.002--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Sinusitis22.07.03.007; 11.01.13.005--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
The 1th Page    1 2    Next   Last    Total 2 Pages